Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II

Not yet recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Novel Oral AnticoagulantsNOACsRivaroxabanApixabanEdoxabanDabigatranTicagrelorPharmacodynamicsPharmacogenomicsRNA ProfileBleedingBiomarker
Interventions
GENETIC

Detection of genotype and RNA profile in platelet and white blood cell

Detection of genotype by next generation sequencing Detection of RNA profile in platelet and white blood cell by RNA sequencing

OTHER

Indicators test related to coagulation function

Indicators test including prothrombin time (PT), activated partial thrombin time (APTT), thrombin time (TT), diluted TT (dTT), snake vein enzyme coagulation time (ECT), anti-XA or IIa activity, etc.

OTHER

Indicators test related to platelet function

Indicators test related to platelet function. Platelet reactivity was measured by VASP. Platelet aggregation rate was measured by turbidimetric method. Platelet and fibrinolytic function were measured by thrombologram, etc.

Trial Locations (6)

Unknown

Anhui Provincial Hospital#The First Affiliated Hospital Of USTC#, Hefei

Peking University First Hospital, Beijing

The Second Affiliated Hospital Of Chongqing Medical University, Chongqing

The 7th People's Hospital of Zhengzhou, Zhengzhou

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai

Zhongshan Hospital FuDan University, Shanghai

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II | Biotech Hunter | Biotech Hunter